Journal article
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
S Branford, DT Yeung, WT Parker, ND Roberts, L Purins, JA Braley, HK Altamura, AL Yeoman, J Georgievski, BA Jamison, S Phillis, Z Donaldson, M Leong, L Fletcher, JF Seymour, AP Grigg, DM Ross, TP Hughes
Blood | Published : 2014
Abstract
In chronic myeloid leukemia (CML) patients, a breakpoint cluster region-Abelson (BCR-ABL1) value >10% at 3 months of therapy is statistically associated with poorer outcome, yetmanyof these patients still achieve satisfactory outcomes. We in vestigated 528 first-lineimatinib-treated patients to determine whether patients with the poorestoutcome can be better discriminated at 3 months. All outcomes were significantly superior for the 410 patients with BCR-ABL1 ≤10% at 3 months (P 10% at 3 months were identified by the rate of BCR-ABL1 decline from baseline, assessed by estimating the number of days over which BCR-ABL1 halved. Patients with BCR-ABL1 halving time <76 days (n = 74) had significa..
View full abstractGrants
Funding Acknowledgements
This work was supported by the Australasian Leukaemia and Lymphoma Group and Novartis, including research support to S.B., T.P.H., D.T.Y., and D.M.R. D.T.Y. is supported by a scholarship from the Leukaemia Foundation of Australia and the AR Clarkson Foundation. W.T.P. is funded by a postdoctoral fellowship from the Leukaemia Foundation of Australia/Cure Cancer Australia.